Measuring neuro progress

Company IPO Status
Algos (ALGO) $49.0M Merged with Endo (ENDP) in Dec. '99 after receiving a non-approvable letter from the FDA in Aug. '99 for MorphiDex (combination of morphine opioid analgesic with dextromethorphan NMDA receptor antagonist) to treat moderate to severe cancer pain
Diacrin (DCRN) $20.0M Ph II trial with porcine neural cell product missed end point in March in Parkinson's disease (PD); several Ph I trials ongoing in other areas